Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT in Lung Cancer

Although 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) is a sensitive nuclear medicine modality, specificity for characterizing lung cancer is limited. Tumor proliferation and early response to molecularly targeted therapy could be visualized us...

Descripción completa

Detalles Bibliográficos
Autores principales: Kairemo, Kalevi, Santos, Elmer B., Macapinlac, Homer A., Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169847/
https://www.ncbi.nlm.nih.gov/pubmed/31935818
http://dx.doi.org/10.3390/diagnostics10010026
_version_ 1783523808384122880
author Kairemo, Kalevi
Santos, Elmer B.
Macapinlac, Homer A.
Subbiah, Vivek
author_facet Kairemo, Kalevi
Santos, Elmer B.
Macapinlac, Homer A.
Subbiah, Vivek
author_sort Kairemo, Kalevi
collection PubMed
description Although 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) is a sensitive nuclear medicine modality, specificity for characterizing lung cancer is limited. Tumor proliferation and early response to molecularly targeted therapy could be visualized using 3′-deoxy-3′[(18)F]-fluorothymidine ((18)F-FLT) PET/CT. The superiority of (18)F-FLT PET/CT over (18)F-FDG PET/CT in early therapeutic monitoring has been well described in patients after chemotherapy, radiotherapy, and/or chemo/radiotherapy. In thispilot study, we explorethe use of (18)F-FLT PET/CT as an early response evaluation modality in patients with lung cancerand provide specific case studies of patients with small cell lung cancer and non-small cell lung cancer who received novel targeted therapies. Early response for c-MET inhibitor was observed in four weeks and for MDM2 inhibitor in nine days.
format Online
Article
Text
id pubmed-7169847
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71698472020-04-22 Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT in Lung Cancer Kairemo, Kalevi Santos, Elmer B. Macapinlac, Homer A. Subbiah, Vivek Diagnostics (Basel) Article Although 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) is a sensitive nuclear medicine modality, specificity for characterizing lung cancer is limited. Tumor proliferation and early response to molecularly targeted therapy could be visualized using 3′-deoxy-3′[(18)F]-fluorothymidine ((18)F-FLT) PET/CT. The superiority of (18)F-FLT PET/CT over (18)F-FDG PET/CT in early therapeutic monitoring has been well described in patients after chemotherapy, radiotherapy, and/or chemo/radiotherapy. In thispilot study, we explorethe use of (18)F-FLT PET/CT as an early response evaluation modality in patients with lung cancerand provide specific case studies of patients with small cell lung cancer and non-small cell lung cancer who received novel targeted therapies. Early response for c-MET inhibitor was observed in four weeks and for MDM2 inhibitor in nine days. MDPI 2020-01-06 /pmc/articles/PMC7169847/ /pubmed/31935818 http://dx.doi.org/10.3390/diagnostics10010026 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kairemo, Kalevi
Santos, Elmer B.
Macapinlac, Homer A.
Subbiah, Vivek
Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT in Lung Cancer
title Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT in Lung Cancer
title_full Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT in Lung Cancer
title_fullStr Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT in Lung Cancer
title_full_unstemmed Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT in Lung Cancer
title_short Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT in Lung Cancer
title_sort early response assessment to targeted therapy using 3′-deoxy-3′[(18)f]-fluorothymidine ((18)f-flt) pet/ct in lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169847/
https://www.ncbi.nlm.nih.gov/pubmed/31935818
http://dx.doi.org/10.3390/diagnostics10010026
work_keys_str_mv AT kairemokalevi earlyresponseassessmenttotargetedtherapyusing3deoxy318ffluorothymidine18ffltpetctinlungcancer
AT santoselmerb earlyresponseassessmenttotargetedtherapyusing3deoxy318ffluorothymidine18ffltpetctinlungcancer
AT macapinlachomera earlyresponseassessmenttotargetedtherapyusing3deoxy318ffluorothymidine18ffltpetctinlungcancer
AT subbiahvivek earlyresponseassessmenttotargetedtherapyusing3deoxy318ffluorothymidine18ffltpetctinlungcancer

Ejemplares similares